Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021146322 - CIRCULATING TUMOR DNA AS A BIOMARKER FOR LEUKEMIA TREATMENT

Publication Number WO/2021/146322
Publication Date 22.07.2021
International Application No. PCT/US2021/013287
International Filing Date 13.01.2021
IPC
A61P 35/02 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
C12Q 1/6886 2018.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
G16H 50/20 2018.1
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
20for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 2018.1
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
30for calculating health indices; for individual health risk assessment
G16B 20/00 2019.1
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
20ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Applicants
  • CARDIFF ONCOLOGY, INC. [US]/[US]
Inventors
  • SAMUELSZ, Errin
  • ERLANDER, Mark
  • RIDINGER, Maya
Agents
  • CHANG, Y, Paul
Priority Data
62/960,16613.01.2020US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CIRCULATING TUMOR DNA AS A BIOMARKER FOR LEUKEMIA TREATMENT
(FR) UTILISATION D'ADN TUMORAL CIRCULANT EN TANT QUE BIOMARQUEUR POUR LE TRAITEMENT DE LA LEUCÉMIE
Abstract
(EN)
Provided herein includes a method comprising analyzing circulating tumor DNA (ctDNA), for example ctDNA in plasma, from a patient with leukemia, to predict and/or determine clinical response. The leukemia can be, for example, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or chronic melomonocytic leukemia (CMML).
(FR)
La présente invention concerne un procédé comprenant l'analyse d'ADN tumoral circulant (ADNtc), par exemple d'ADNtc dans un plasma, à partir d'un patient atteint de leucémie, pour prédire et/ou déterminer une réponse clinique. La leucémie peut être, par exemple, la leucémie myéloïde aiguë (LAM), le syndrome myélodysplasique (SMD) ou la leucémie myélomonocytaire chronique (LMMC).
Latest bibliographic data on file with the International Bureau